Published in

Wiley, Bipolar Disorders, 1(25), p. 43-55, 2022

DOI: 10.1111/bdi.13271

Links

Tools

Export citation

Search in Google Scholar

Bipolar I and bipolar II subtypes in older age: Results from the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE‐BD) project

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractObjectivesThe distinction between bipolar I disorder (BD‐I) and bipolar II disorder (BD‐II) has been a topic of long‐lasting debate. This study examined differences between BD‐I and BD‐II in a large, global sample of OABD, focusing on general functioning, cognition and somatic burden as these domains are often affected in OABD.MethodsCross‐sectional analyses were conducted with data from the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE‐BD) database. The sample included 963 participants aged ≥50 years (714 BD‐I, 249 BD‐II). Sociodemographic and clinical factors were compared between BD subtypes including adjustment for study cohort. Multivariable analyses were conducted with generalized linear mixed models (GLMMs) and estimated associations between BD subtype and (1) general functioning (GAF), (2) cognitive performance (g‐score) and (3) somatic burden, with study cohort as random intercept.ResultsAfter adjustment for study cohort, BD‐II patients more often had a late onset ≥50 years (p = 0.008) and more current severe depression (p = 0.041). BD‐I patients were more likely to have a history of psychiatric hospitalization (p < 0.001) and current use of anti‐psychotics (p = 0.003). Multivariable analyses showed that BD subtype was not related to GAF, cognitive g‐score or somatic burden.ConclusionBD‐I and BD‐II patients did not differ in terms of general functioning, cognitive impairment or somatic burden. Some clinical differences were observed between the groups, which could be the consequence of diagnostic definitions. The distinction between BD‐I and BD‐II is not the best way to subtype OABD patients. Future research should investigate other disease specifiers in this population.